Fmr LLC Has $27.42 Million Stake in Advaxis, Inc. (ADXS)
Fmr LLC lessened its position in Advaxis, Inc. (NASDAQ:ADXS) by 1.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,225,380 shares of the biotechnology company’s stock after selling 62,400 shares during the period. Fmr LLC owned about 10.44% of Advaxis worth $27,423,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marshall Wace North America L.P. bought a new position in Advaxis during the first quarter valued at approximately $2,455,000. MARSHALL WACE ASIA Ltd bought a new position in Advaxis during the first quarter valued at approximately $2,455,000. Vanguard Group Inc. lifted its position in Advaxis by 9.2% during the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock valued at $13,587,000 after purchasing an additional 139,710 shares during the period. Parametric Portfolio Associates LLC lifted its position in Advaxis by 116.3% during the first quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock valued at $707,000 after purchasing an additional 46,559 shares during the period. Finally, Tudor Investment Corp ET AL bought a new position in Advaxis during the first quarter valued at approximately $283,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.
In related news, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of Advaxis stock in a transaction that occurred on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total value of $2,580,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.21% of the stock is owned by company insiders.
A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th. Cantor Fitzgerald set a $19.00 price objective on shares of Advaxis and gave the company a “buy” rating in a research report on Thursday, July 6th. Finally, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research report on Friday, September 15th.
Advaxis, Inc. (ADXS) opened at 3.79 on Monday. The company’s 50-day moving average is $4.88 and its 200-day moving average is $6.67. Advaxis, Inc. has a 12 month low of $3.76 and a 12 month high of $10.88. The company’s market cap is $155.64 million.
Advaxis (NASDAQ:ADXS) last released its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. On average, equities research analysts expect that Advaxis, Inc. will post ($2.23) EPS for the current fiscal year.
WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/23/fmr-llc-has-27-42-million-stake-in-advaxis-inc-adxs.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Want to see what other hedge funds are holding ADXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Advaxis, Inc. (NASDAQ:ADXS).
Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.